Ozempic is not insulin: what its label says it is
No. Ozempic is semaglutide, and its label calls it a GLP-1 receptor agonist: it prompts your own pancreas to release insulin when blood sugar is high. Insulin is a different medicine, and the Ozempic label treats it as one, warning about taking both together and reporting trials that tested semaglutide against insulin glargine.
Reviewed by Ellis Brandt. Sources checked September 2026.
This guide draws on the cited FDA-approved prescribing information and other FDA sources. It is not medical advice; discuss treatment with your clinician. See the medical disclaimer.
What the label says Ozempic is
The first line of the Ozempic label’s highlights names the class: “OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist”, indicated “as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus”. Insulin appears nowhere in it.
What the drug does with insulin is in section 7.1, in one line: “OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations.” The insulin is yours. Section 12.1 adds the qualifier that matters: semaglutide stimulates insulin secretion and lowers glucagon secretion “both in a glucose-dependent manner”, so “when blood glucose is high, insulin secretion is stimulated, and glucagon secretion is inhibited.” An injection of insulin does not wait to be asked.
That difference runs through the rest of the label. How the drug works in full is on how GLP-1 drugs work.
Insulin is on the same label, as a different drug
Insulin is all over these four labels, always as a separate drug the patient may already be taking.
Drag the table sideways to read the remaining columns.
| Label | Where insulin is named | What the label says about it |
|---|---|---|
| Ozempic | Section 5.5, section 7.1, and the trials in section 14.1 | A patient taking insulin or a sulfonylurea alongside Ozempic “may have an increased risk of hypoglycemia, including severe hypoglycemia”, and the label says to consider reducing the insulin dose when starting. Its efficacy “was compared with placebo, sitagliptin, exenatide extended-release (ER), and insulin glargine”. |
| Wegovy | Section 5.4 | The same hypoglycemia warning for patients with diabetes, and a line that goes further: “The use of WEGOVY in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.” |
| Mounjaro | Section 5.3 and section 7.1 | Same shape of warning for tirzepatide: taking it with insulin or an insulin secretagogue raises the risk of hypoglycemia, and the label says to consider reducing that other dose. |
| Zepbound | Section 5.7 and section 7.1 | “ZEPBOUND lowers blood glucose and can cause hypoglycemia”, and the risk is higher in combination with insulin or a sulfonylurea. The label says to consider reducing the insulin or sulfonylurea dose when starting. |
Read that column again and the answer is plain: a drug that replaced insulin would not need a warning about taking insulin with it. Which diabetes medicines each label flags, and what it says to do about them, is on the drug interactions page.
Is tirzepatide a GLP-1?
Yes, and one more besides. Both tirzepatide labels open with the same description: Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, and Zepbound’s section 1 says the same of it. So tirzepatide is a GLP-1 receptor agonist, and it acts on a second receptor as well, for a hormone called glucose-dependent insulinotropic polypeptide.
That matters for a practical reason: both weight-loss labels tell you not to stack them. Zepbound’s limitation of use reads “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended”, and Wegovy prints the same rule for semaglutide-containing products. Two of these drugs at once is not two treatments.
Why the mix-up matters when you are reading a price
“GLP-1” is a class, not a product. A seller advertising a monthly price for a GLP-1 may be pricing semaglutide, tirzepatide, an injection, a tablet, a branded pen or a compounded vial, and those are different things with different labels behind them. Of the published prices read for this site, many never name a drug at all.
None of them is insulin. If a page offers you insulin and a GLP-1 in the same sentence, the labels above say those are two prescriptions, not one, and that taking both is a conversation with a prescriber rather than a checkout choice.
Sources
Drag the table sideways to read the remaining columns.
| Label | Applicant on the label | SPL version | Label effective date | Where it was read |
|---|---|---|---|---|
| Ozempic (semaglutide) | Novo Nordisk Pharmaceutical Industries, LP | 20 | 2026-06-01 | DailyMed, set id adec4fd2-6858-4c99-91d4-531f5f2a2d79 |
| Wegovy (semaglutide) | Novo Nordisk Pharmaceutical Industries, LP | 19 | 2026-06-18 | DailyMed, set id ee06186f-2aa3-4990-a760-757579d8f77b |
| Mounjaro (tirzepatide) | Eli Lilly and Company | 40 | 2026-08-27 | DailyMed, set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0 |
| Zepbound (tirzepatide) | Eli Lilly and Company | 40 | 2026-08-28 | DailyMed, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b |
The drug class and the indications are from section 1 of each label; the insulin lines are from sections 5 and 7, and the comparator list is from Ozempic's section 14.1. Every figure and quotation comes from the label’s own tables and text. Each label is the FDA-approved version that was current when it was read in September 2026, identified in the table by its version number and effective date.
See the providers
What a seller dispenses is a property of its prescription, not of its marketing. The boards list who sells each molecule and what each one publishes.
- Semaglutide providersprovider board
Compare semaglutide plans, pharmacy details and cancellation terms.
- Tirzepatide providersprovider board
Compare tirzepatide plans, pharmacy details and cancellation terms.
More, read from the same labels
- First-year GLP-1 costsresearch guide
A low monthly headline does not tell you what a year of treatment will cost. Compare the same medication and service package, then separate the total you expect to spend from the amount you must pay before treatment begins.
- Cancellation and refundsresearch guide
Canceling future membership charges, stopping an upcoming medication order and requesting a refund are three different requests. Get a written answer for each one that applies to you.
- Insurance denial documentsresearch guide
The next step depends on why coverage was denied. A missing document, a formulary restriction and an excluded benefit are different problems. Start with the written decision before paying someone to submit another request.
- Savings and cash-pay eligibilityresearch guide
A manufacturer savings card and a self-pay offer can have different eligibility rules, even for the same medicine. Match the offer to your coverage and exact product before using its advertised price in your budget.
- Verify your GLP-1 pharmacyresearch guide
The website taking your payment, the clinician prescribing and the pharmacy dispensing may be different businesses. Identify each one. A recognizable brand or a reassuring badge does not tell you who will fill the prescription.
- Changing GLP-1 providersresearch guide
Before ending your current service, establish what the new practice needs, what it will charge and when it can evaluate you. Transferring your records does not guarantee that another clinician will continue the same prescription.
- Weight regain after stoppingresearch guide
Weight regain occurred after treatment withdrawal in studies of semaglutide and tirzepatide. The findings support planning follow-up and affordability before an interruption, but they do not predict exactly what will happen to one person.
- Semaglutide vs tirzepatideresearch guide
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- How they workresearch guide
The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.
- Zepbound vs Ozempicresearch guide
Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.
- Dose escalation schedulesresearch guide
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesresearch guide
What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.
- Hair lossresearch guide
Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.
- Fatigue and tirednessresearch guide
Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.
- Missed dose rulesresearch guide
The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.
- Drug interactionsresearch guide
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlineresearch guide
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Zepbound by doseresearch guide
What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.
- Zepbound at 3 monthsresearch guide
What does the Zepbound label report about three-month weight loss and maintenance dosing?
- Injecting tirzepatideresearch guide
The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.
- Refrigeration and storageresearch guide
How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.
- Who should not take oneresearch guide
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.
The short answer
| Ozempic | semaglutide, a GLP-1 |
|---|---|
| Wegovy | semaglutide, a GLP-1 |
| Mounjaro | tirzepatide, GIP and GLP-1 |
| Zepbound | tirzepatide, GIP and GLP-1 |
| Insulin | none of the four |
Each drug class is the phrase printed in that label’s own section 1.